Wells Fargo’s Surface Oncology, Inc. Common Stock SURF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-880
| Closed | -$765 | – | 7741 |
|
|
2023
Q2 | $765 | Buy |
880
+16
| +2% | +$11 | ﹤0.01% | 6389 |
|
|
2023
Q1 | $603 | Buy |
864
+105
| +14% | +$85 | ﹤0.01% | 6508 |
|
|
2022
Q4 | $622 | Buy |
759
+24
| +3% | +$24 | ﹤0.01% | 6325 |
|
|
2022
Q3 | $0 | Buy |
735
+61
| +9% | +$97 | ﹤0.01% | 7701 |
|
|
2022
Q2 | $1K | Sell |
674
-130,051
| -99% | -$270K | ﹤0.01% | 6682 |
|
|
2022
Q1 | $384K | Sell |
130,725
-6,642
| -5% | -$23.3K | ﹤0.01% | 4588 |
|
|
2021
Q4 | $656K | Sell |
137,367
-215,695
| -61% | -$1.39M | ﹤0.01% | 4452 |
|
|
2021
Q3 | $2.67M | Buy |
353,062
+346,235
| +5,072% | +$2.22M | ﹤0.01% | 3420 |
|
|
2021
Q2 | $51K | Sell |
6,827
-25,015
| -79% | -$193K | ﹤0.01% | 5549 |
|
|
2021
Q1 | $249K | Sell |
31,842
-2,737
| -8% | -$27.4K | ﹤0.01% | 5063 |
|
|
2020
Q4 | $318K | Buy |
34,579
+34,449
| +26,499% | +$299K | ﹤0.01% | 4841 |
|
|
2020
Q3 | $1K | Buy |
130
+66
| +103% | +$400 | ﹤0.01% | 6254 |
|
|
2020
Q2 | $0 | Buy |
64
+1
| +2% | +$4 | ﹤0.01% | 7015 |
|
|
2020
Q1 | $0 | Buy |
+63
| New | +$166 | ﹤0.01% | 7016 |
|
|
2019
Q3 | – | Sell |
-568
| Closed | -$2K | – | 6830 |
|
|
2019
Q2 | $2K | Sell |
568
-17,840
| -97% | -$71K | ﹤0.01% | 6197 |
|
|
2019
Q1 | $88K | Sell |
18,408
-2,474
| -12% | -$12.2K | ﹤0.01% | 5175 |
|
|
2018
Q4 | $89K | Buy |
20,882
+19,772
| +1,781% | +$153K | ﹤0.01% | 5338 |
|
|
2018
Q3 | $12K | Buy |
1,110
+219
| +25% | +$2.57K | ﹤0.01% | 5956 |
|
|
2018
Q2 | $15K | Buy |
+891
| New | +$12.9K | ﹤0.01% | 5882 |
|
Wells Fargo's SURF Position: Q3 2023 in Review
Wells Fargo sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2023, closing a stake of 880 shares — an estimated $765 sold.
Wells Fargo first reported a position in SURF in Q2 2018 and held it in 19 quarters. The position peaked at $2.67M in Q3 2021. 0 funds tracked by Wall St. Rank hold SURF as of Q3 2023.
- Wells Fargo reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Wells Fargo sold 880 Surface Oncology, Inc. Common Stock shares in Q3 2023, an estimated $765.
- Wells Fargo first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 19 quarters.
- Wells Fargo's Surface Oncology, Inc. Common Stock position peaked at $2.67M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2023.
Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.